<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Med</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Med</journal-id><journal-id journal-id-type="publisher-id">jcm</journal-id><journal-title-group><journal-title>Journal of Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2077-0383</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680078</article-id><article-id pub-id-type="doi">10.3390/jcm13247729</article-id><article-id pub-id-type="publisher-id">jcm-13-07729</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The Role of Radioiodine Therapy in Differentiated Thyroid Cancer Arising from Struma Ovarii: A Systematic Review</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3599-0492</contrib-id><name><surname>Bellini</surname><given-names>Pietro</given-names></name><xref rid="af1-jcm-13-07729" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4839-9033</contrib-id><name><surname>Dondi</surname><given-names>Francesco</given-names></name><xref rid="af2-jcm-13-07729" ref-type="aff">2</xref><xref rid="c1-jcm-13-07729" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Zilioli</surname><given-names>Valentina</given-names></name><xref rid="af1-jcm-13-07729" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4460-3746</contrib-id><name><surname>Gatta</surname><given-names>Elisa</given-names></name><xref rid="af3-jcm-13-07729" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Cavadini</surname><given-names>Maria</given-names></name><xref rid="af3-jcm-13-07729" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4317-1232</contrib-id><name><surname>Cappelli</surname><given-names>Carlo</given-names></name><xref rid="af3-jcm-13-07729" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Vigan&#x000f2;</surname><given-names>Gian Luca</given-names></name><xref rid="af4-jcm-13-07729" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Bertagna</surname><given-names>Francesco</given-names></name><xref rid="af2-jcm-13-07729" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Tarallo</surname><given-names>Mariarita</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Fiori</surname><given-names>Enrico</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-jcm-13-07729"><label>1</label>Nuclear Medicine, ASST Spedali Civili di Brescia, 25123 Brescia, Italy; <email>bpietro.bellini@asst-spedalicivili.it</email> (P.B.); <email>valentina.zilioli@asst-spedalicivili.it</email> (V.Z.)</aff><aff id="af2-jcm-13-07729"><label>2</label>Nuclear Medicine, ASST Spedali Civili di Brescia and Universit&#x000e0; Degli Studi di Brescia, 25123 Brescia, Italy; <email>francesco.bertagna@unibs.it</email></aff><aff id="af3-jcm-13-07729"><label>3</label>Unit of Endocrinology and Metabolism, ASST Spedali Civili di Brescia and Universit&#x000e0; Degli Studi di Brescia, 25123 Brescia, Italy; <email>elisa.gatta@unibs.it</email> (E.G.); <email>m.cavadini@unibs.it</email> (M.C.); <email>carlo.cappelli@unibs.it</email> (C.C.)</aff><aff id="af4-jcm-13-07729"><label>4</label>Clinical Engineering, ASST Spedali Civili di Brescia, 25123 Brescia, Italy; <email>gianluca.vigano@asst-spedalicivili.it</email></aff><author-notes><corresp id="c1-jcm-13-07729"><label>*</label>Correspondence: <email>francesco.dondi@unibs.it</email></corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>13</volume><issue>24</issue><elocation-id>7729</elocation-id><history><date date-type="received"><day>25</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>09</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>12</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background</bold>: Struma ovarii (SO) is an ovarian teratoma with the presence of ectopic thyroid tissue. Differentiated thyroid cancer (DTC) in SO is a rare finding. Management of DTC in SO is currently not clearly established. We performed a systematic review of the literature to assess the role of 131I radiometabolic therapy in the treatment of DTC in SO. <bold>Methods</bold>: a wide literature search in the Scopus, PubMed/MEDLINE, and Web of Science databases was made to find published articles regarding the treatment of patients with DTC and SO. The quality assessment of studies was performed by QUADAS-2 evaluation. <bold>Results</bold>: eleven studies were included in the systematic review. All of them were retrospective studies and/or case series, and two of them also included a review of the literature. Most of the studies describe cases of DTC in SO treated by total thyroidectomy (TT) and subsequent radioiodine (RAI) therapy, especially in patients with distant metastases and/or concomitant thyroid cancer. However, the majority of patients apparently did not require radiometabolic therapy. <bold>Conclusions</bold>: TT and subsequent RAI therapy is usually performed in metastatic disease, not recommended in patients with intraovarian disease without risk factors, and it appeared possible but not mandatory in patients with risk factors.</p></abstract><kwd-group><kwd>struma ovarii</kwd><kwd>differentiated thyroid cancer</kwd><kwd>systematic review</kwd><kwd>radioiodine</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-jcm-13-07729"><title>1. Introduction</title><p>Ovarian teratoma (OT) is a germinal cell tumor of the ovary that contains different ectopic tissues, and the presence of thyroid tissue is frequent. Struma ovarii (SO) was first described by Boettlin in 1889 and reported by Gottshalk [<xref rid="B1-jcm-13-07729" ref-type="bibr">1</xref>] and is defined as an OT with the presence of thyroid tissue involving more than 50% of the lesion. It represents a rare finding regarding less than 5% of the OT [<xref rid="B2-jcm-13-07729" ref-type="bibr">2</xref>]. Malignant SO (MSO) is also rare and could be represented by differentiated thyroid cancer (DTC), highly differentiated follicular carcinoma (HDFC) that is a specific type of follicular neoplasia with histological characteristics of a benign lesion but aggressive behavior involving tissue outside the ovary, carcinoid and other thyroid cancer type [<xref rid="B3-jcm-13-07729" ref-type="bibr">3</xref>,<xref rid="B4-jcm-13-07729" ref-type="bibr">4</xref>]. DTC is the most frequent finding in MSO, particularly papillary thyroid cancer, representing about 44.8&#x02013;62.5% of them [<xref rid="B3-jcm-13-07729" ref-type="bibr">3</xref>,<xref rid="B4-jcm-13-07729" ref-type="bibr">4</xref>,<xref rid="B5-jcm-13-07729" ref-type="bibr">5</xref>], and it is, in most cases, confined to the ovary. Although DTC in MSO appears as a tumor with a good prognosis, and recrudescence after surgical resection is rare [<xref rid="B5-jcm-13-07729" ref-type="bibr">5</xref>,<xref rid="B6-jcm-13-07729" ref-type="bibr">6</xref>], several patients could present metastases at the diagnosis or in the follow-up (FU) [<xref rid="B7-jcm-13-07729" ref-type="bibr">7</xref>,<xref rid="B8-jcm-13-07729" ref-type="bibr">8</xref>] and, also due to its rarity and possible involvement of multiple professional figures, currently there are no shared guidelines focusing on the management of the DTC in MSO.</p><p>Nevertheless, DTC developed in the thyroid gland has well-established management described by several international guidelines that are represented by initial treatment with surgery followed in specific cases by radioiodine therapy (RAI) [<xref rid="B9-jcm-13-07729" ref-type="bibr">9</xref>,<xref rid="B10-jcm-13-07729" ref-type="bibr">10</xref>,<xref rid="B11-jcm-13-07729" ref-type="bibr">11</xref>]. Particularly, the American Thyroid Association guidelines [<xref rid="B9-jcm-13-07729" ref-type="bibr">9</xref>] suggest the use of RAI in cases of DTC with metastases, with a high risk of disease recrudescence, and the possibility to consider the treatment also in patients with intermediate and low risk of disease relapse. In addition, FU and further treatment are guided by the persistence of biochemical and/or structural disease [<xref rid="B12-jcm-13-07729" ref-type="bibr">12</xref>,<xref rid="B13-jcm-13-07729" ref-type="bibr">13</xref>,<xref rid="B14-jcm-13-07729" ref-type="bibr">14</xref>], the 131I avidity of the malignant tissue [<xref rid="B15-jcm-13-07729" ref-type="bibr">15</xref>,<xref rid="B16-jcm-13-07729" ref-type="bibr">16</xref>,<xref rid="B17-jcm-13-07729" ref-type="bibr">17</xref>,<xref rid="B18-jcm-13-07729" ref-type="bibr">18</xref>], and the results of other diagnostic imaging examinations, such as <sup>18</sup>F-fluorodesoxyglucose ([<sup>18</sup>F]FDG) positron emission tomography/computed tomography (PET/CT) [<xref rid="B19-jcm-13-07729" ref-type="bibr">19</xref>,<xref rid="B20-jcm-13-07729" ref-type="bibr">20</xref>].</p><p>The aim of this systematic review (SR) is, therefore, to evaluate the role of RAI in the treatment strategy of patients with DTC in SO, focusing in particular on describing the target of patients that could benefit from this therapeutic approach.</p></sec><sec id="sec2-jcm-13-07729"><title>2. Materials and Methods</title><p>This systematic review was performed according to the &#x0201c;Preferred Reporting Items for a Systematic Review and Meta-Analysis&#x0201d; (PRISMA 2020 statement), employed as a guide in its development [<xref rid="B21-jcm-13-07729" ref-type="bibr">21</xref>]. The complete PRISMA checklist is in the <xref rid="app1-jcm-13-07729" ref-type="app">Supplementary Material</xref>. Pre-registering was not carried out.</p><sec id="sec2dot1-jcm-13-07729"><title>2.1. Search Strategy</title><p>A comprehensive literature search in the Scopus, PubMed/MEDLINE, and Web of Science databases was performed to identify published articles on patients with DTC growth in SO. The algorithm used to search the articles was (&#x0201c;struma&#x0201d;) AND (&#x0201c;ovarii&#x0201d;) AND (&#x0201c;thyroid&#x0201d;) AND (&#x0201c;cancer&#x0201d;): due to the rarity of the disease, we chose to search all articles focusing on DTC development from SO, subsequently extracting only papers that focus on the possible role of RAI therapy. The search was updated to 30 June 2024, and no date limit was considered for the beginning. Articles in languages other than English were not included in the review. Despite the rarity of the disease, considering the systematic nature of the review, only original articles and case series with at least four patients affected by the disease were included. Instead, conference relations, case reports, reviews, preclinical studies, or editorials were not considered. Hybrid articles (e.g., case series plus review and/or retrospective cohort studies plus review) were only considered if at least four patients were included in the original part; these criteria were used to ensure the experience of the authors in the specific field in the selection, distribution, and outcome of the patients. In addition, the references of the retrieved articles were screened to find relevant articles to include in the review.</p></sec><sec id="sec2dot2-jcm-13-07729"><title>2.2. Study Selection</title><p>The titles and abstract of the selected articles were independently reviewed by two researchers (P.B., F.D.) who subsequently read the full-text version of the articles in the field of the review. Articles without unanimous consent were evaluated by a third expert physician (F.B.).</p></sec><sec id="sec2dot3-jcm-13-07729"><title>2.3. Quality Assessment</title><p>The quality assessment of the studies selected was performed using the Quality Assessment of Diagnostic Accuracy Studies version 2 (QUADAS-2) evaluation [<xref rid="B22-jcm-13-07729" ref-type="bibr">22</xref>]. Quality assessment was performed independently by two reviewers.</p></sec><sec id="sec2dot4-jcm-13-07729"><title>2.4. Data Extraction</title><p>Each study included in the review was carefully evaluated, and the basic data extracted (author names, design of the study, country of origin, years of publication, number of patients, etc.&#x02026;). The results section reported the main findings of every article considered in the review.</p></sec><sec id="sec2dot5-jcm-13-07729"><title>2.5. Literature Search Findings</title><p>The literature search identified a total of 553 articles. After evaluating the titles and the abstracts of each study, 224 of them were excluded because they were not in the field of interest of the review, 216 because they were case reports and/or case series with less than 4 patients, 68 because they were reviews and 31 for other different reasons (language different than English, other type of documents such as Editorials, communications, book chapters and article corrections, hybrid studies where the selection and/or distribution of patients is not clear etc.&#x02026;). Fourteen articles were consequently selected, and the full-text version of each one was retrieved [<xref rid="B3-jcm-13-07729" ref-type="bibr">3</xref>,<xref rid="B5-jcm-13-07729" ref-type="bibr">5</xref>,<xref rid="B6-jcm-13-07729" ref-type="bibr">6</xref>,<xref rid="B7-jcm-13-07729" ref-type="bibr">7</xref>,<xref rid="B23-jcm-13-07729" ref-type="bibr">23</xref>,<xref rid="B24-jcm-13-07729" ref-type="bibr">24</xref>,<xref rid="B25-jcm-13-07729" ref-type="bibr">25</xref>,<xref rid="B26-jcm-13-07729" ref-type="bibr">26</xref>,<xref rid="B27-jcm-13-07729" ref-type="bibr">27</xref>,<xref rid="B28-jcm-13-07729" ref-type="bibr">28</xref>,<xref rid="B29-jcm-13-07729" ref-type="bibr">29</xref>,<xref rid="B30-jcm-13-07729" ref-type="bibr">30</xref>,<xref rid="B31-jcm-13-07729" ref-type="bibr">31</xref>,<xref rid="B32-jcm-13-07729" ref-type="bibr">32</xref>]. Li S et al. wrote 3 of the 14 papers included in the review: the articles of Li S et al. considered the same group of patients, and consequently, we selected only the most recent paper [<xref rid="B5-jcm-13-07729" ref-type="bibr">5</xref>,<xref rid="B28-jcm-13-07729" ref-type="bibr">28</xref>]. Furthermore, the study of SC Yoo et al. presented some important data lacking and/or incongruence (e.g., the reporting of different numbers of patients in the sample between the abstract and the main document, lack of specification of the type of malignancy in MSO cases, etc.&#x02026;) and could not be considered for the SR [<xref rid="B32-jcm-13-07729" ref-type="bibr">32</xref>]. Finally, we included in the systematic review 11 articles [<xref rid="B3-jcm-13-07729" ref-type="bibr">3</xref>,<xref rid="B6-jcm-13-07729" ref-type="bibr">6</xref>,<xref rid="B7-jcm-13-07729" ref-type="bibr">7</xref>,<xref rid="B23-jcm-13-07729" ref-type="bibr">23</xref>,<xref rid="B24-jcm-13-07729" ref-type="bibr">24</xref>,<xref rid="B25-jcm-13-07729" ref-type="bibr">25</xref>,<xref rid="B26-jcm-13-07729" ref-type="bibr">26</xref>,<xref rid="B27-jcm-13-07729" ref-type="bibr">27</xref>,<xref rid="B29-jcm-13-07729" ref-type="bibr">29</xref>,<xref rid="B30-jcm-13-07729" ref-type="bibr">30</xref>,<xref rid="B31-jcm-13-07729" ref-type="bibr">31</xref>]. After screening the references of the selected studies, no other articles were found to be suitable for inclusion in the review (<xref rid="jcm-13-07729-f001" ref-type="fig">Figure 1</xref>).</p></sec></sec><sec sec-type="results" id="sec3-jcm-13-07729"><title>3. Results</title><p>Quality assessment using QUADAS-2 showed that some studies had a high risk of bias in the applicability of patient selection due to the numerical limitation of the samples considered [<xref rid="B24-jcm-13-07729" ref-type="bibr">24</xref>,<xref rid="B26-jcm-13-07729" ref-type="bibr">26</xref>,<xref rid="B29-jcm-13-07729" ref-type="bibr">29</xref>,<xref rid="B30-jcm-13-07729" ref-type="bibr">30</xref>,<xref rid="B31-jcm-13-07729" ref-type="bibr">31</xref>]. In addition, all studies had limitations in sequence and timing due to the retrospective design and variability in patients&#x02019; follow-up, which were not considered relevant. Moreover, with regard to flow and timing, 13.33% of patients in the study by Ryu HJ et al. were lost at the follow-up [<xref rid="B23-jcm-13-07729" ref-type="bibr">23</xref>]. Finally, the study by Goffredo P et al. [<xref rid="B6-jcm-13-07729" ref-type="bibr">6</xref>], considering the aim of the systematic review, presented a high risk of bias in the applicability of all items due to the lack of some information (e.g., histological characteristics of MSO and FU results), but remained useful due to its large sample and a clear indication of the number of RAI treatments performed. The result of the quality assessment is shown in <xref rid="jcm-13-07729-f002" ref-type="fig">Figure 2</xref>.</p><p>All the 11 studies included in the SR had a retrospective design [<xref rid="B3-jcm-13-07729" ref-type="bibr">3</xref>,<xref rid="B6-jcm-13-07729" ref-type="bibr">6</xref>,<xref rid="B7-jcm-13-07729" ref-type="bibr">7</xref>,<xref rid="B20-jcm-13-07729" ref-type="bibr">20</xref>,<xref rid="B21-jcm-13-07729" ref-type="bibr">21</xref>,<xref rid="B22-jcm-13-07729" ref-type="bibr">22</xref>,<xref rid="B23-jcm-13-07729" ref-type="bibr">23</xref>,<xref rid="B24-jcm-13-07729" ref-type="bibr">24</xref>,<xref rid="B26-jcm-13-07729" ref-type="bibr">26</xref>,<xref rid="B27-jcm-13-07729" ref-type="bibr">27</xref>,<xref rid="B28-jcm-13-07729" ref-type="bibr">28</xref>], and 2 of them were integrated by a review of the literature [<xref rid="B26-jcm-13-07729" ref-type="bibr">26</xref>,<xref rid="B27-jcm-13-07729" ref-type="bibr">27</xref>]. <xref rid="jcm-13-07729-t001" ref-type="table">Table 1</xref>, <xref rid="jcm-13-07729-t002" ref-type="table">Table 2</xref>, <xref rid="jcm-13-07729-t003" ref-type="table">Table 3</xref> and <xref rid="jcm-13-07729-t004" ref-type="table">Table 4</xref> describe the main characteristics of the studies included in the review, and their main results were also reported.</p><p>Wei S et al. [<xref rid="B3-jcm-13-07729" ref-type="bibr">3</xref>] described a single-center experience in the diagnosis and management of SO, specifically 11 patients with DTC growth in SO. PTC was the predominant histotype (90.6%), and only one patient was diagnosed with highly differentiated follicular cancer of ovarian origin (HDFCO). Only one of the PTC patients and the patient with HDFCO had extraovarian local spread at diagnosis, with the first one developing liver metastases during the FU and undergoing TT and RAI. Another one of the ten DTC patients underwent TT and RAI; the criteria for therapeutic choice were not explained. FU was adequate (mean 79 months) and negative in all these ten patients. Goffredo P et al. [<xref rid="B6-jcm-13-07729" ref-type="bibr">6</xref>] described a large sample of patients obtained by consulting the Surveillance, Epidemiology, and End Results (SEER) database, in particular a selection of 68 patients with MSO defined as &#x0201c;histologically identical to differentiated thyroid carcinoma&#x0201d; considering the World Health Organization (WHO IV) edition of 2003. Unfortunately, the histology was not specified; however, the study described 6 cases of RAI treatment (9.2%), five with RAI alone and one with RAI plus external beam radiation therapy (EBRT). Again, three patients who received RAI had concomitant and/or secondary thyroid cancer. The duration of FU was variable (mean = 96 months, ranging from 2 to 408, standard deviation = 87.6), and the prognosis was excellent (overall survival ratio &#x0003e; 94% at 10 years). Garg K et al. [<xref rid="B7-jcm-13-07729" ref-type="bibr">7</xref>] described a sample of 10 patients based on a single-center experience. In particular, eight patients presented with DTC and two patients with poorly differentiated cancer (PDC). Two patients who developed metastases during follow-up underwent TT and subsequent RAI: the first one had a right ovarian mass and cul-de-sac and omentum involvement at diagnosis but underwent RAI shortly after left adnexal involvement and second major abdominal surgery; the second one underwent RAI after disease recrudescence with peritoneal, liver and cul-de-sac involvement and because of high thyroglobulin levels. Both patients were initially diagnosed with benign SO and were still alive after six years of follow-up. Notably, three patients with classic risk factors in DTC, one with focal vascular invasion, one with surgical margin involvement, and one with infiltrative borders were treated with local surgery only. FU (mean 4.5 years) was negative in the eight patients without metastases. Ryu HJ et al. [<xref rid="B23-jcm-13-07729" ref-type="bibr">23</xref>] presented a retrospective study based on a monocentric experience with 15 cases of MSO. Papillary DTC was the prevalent histotype (46.7%). Three patients presented with peritoneal metastases at diagnosis, and four patients had a history of or were subsequently diagnosed with thyroid cancer. Four patients underwent TT, and three of them received RAI, one for MSO metastases and two because of the presence of thyroid cancer. Notably, one patient with peritoneal metastases underwent only abdominal surgery because she was looking for pregnancy. Two patients were not available for follow-up (FU) assessment and the remaining 13 had a mean FU of 33 months. Of these 13 patients, 11 had negative results, 1 had stable disease, and one experienced disease progression with peritoneal seeding. The latter patients underwent both RAI. Gadducci et al. [<xref rid="B24-jcm-13-07729" ref-type="bibr">24</xref>] presented a retrospective study based on a multicentre experience of 23 patients with malignant ovarian teratoma, in particular 5 patients with DTC in SO. Papillary DTC was the predominant histotype (60%). All patients had a stage I disease, according to the International Federation of Gynecology and Obstetrics (FIGO), and none of them had metastases at the subsequent follow-up. One patient had a previous history of thyroid cancer treated by TT and RAI, but none of the patients carried out RAI after the diagnosis of DTC developed from SO, and the FU (mean 60 months) was negative in all of them. Li S et al. [<xref rid="B25-jcm-13-07729" ref-type="bibr">25</xref>] described a single-center experience in a retrospective study focusing on patients with ovarian strumal disease, specifically 13 patients with DTC in SO. Again, PTC was the most common histotype (46.2%). Three patients had metastases at diagnosis, and six subjects received adjuvant therapy: five received chemotherapy, while one received TT + RAI. The last patient had a partial response and was alive at the end of FU. In addition, three patients relapsed during FU: 1 died after surgical resection and chemotherapy, and two received TT + RAI and achieved a partial response and a complete response, respectively. Addley S. et al. [<xref rid="B26-jcm-13-07729" ref-type="bibr">26</xref>] reported a retrospective monocentric experience analyzing 11 patients with MSO, and 6 of them presented DTC in SO. All of the patients had a PTC, and none of them presented metastases at diagnosis. Three patients with high risk, defined by aggressive histopathological features of PTC, a significant (&#x0003e;15 mm) disease deposit, close surgical margins, and/or lympho-vascular invasion, performed TT and further RAI. None of the subjects had disease relapse and/or died during the FU. The study of Devaney K et al. [<xref rid="B27-jcm-13-07729" ref-type="bibr">27</xref>] described a retrospective analysis based on a monocentric experience of 54 cases of SO, particularly 13 cases of DTC in SO. Eleven patients had a PTC and 2 FTC in SO. There was only one case of peritoneal involvement without other metastases: the patient was treated conservatively only with abdominal surgery and had a partial response. No patients performed TT + RAI, and all of them did not develop disease relapse during the FU (average 87.6 months). Roth LM et al. [<xref rid="B29-jcm-13-07729" ref-type="bibr">29</xref>] presented a case series of four patients from two different centers. Three patients had PTC, all treated with surgery, with one death apparently unrelated to the disease. The last patient had a poorly differentiated FTC invading the uterine wall and also involvement of the peritoneal tissue. This subject was unsuccessfully treated with gynaecological surgery, adjuvant chemotherapy, and TT + RAI and died three years after diagnosis. Marti JL et al. [<xref rid="B30-jcm-13-07729" ref-type="bibr">30</xref>] presented the cases of 4 different patients treated for DTC arising from SO in a single-center experience. Three patients had PTC and one FTC, all of them had the intra-ovarian disease and underwent gynaecological surgery. One patient with 5 cm ovarian PTC also underwent TT + RAI, with the discovery of a 5 mm thyroid cancer with extra-thyroid extension and metastases in central lymph nodes; the criteria for therapeutic choice were not explained. During a median FU of nine years, no patients died and/or had disease recurrence. Poli R et al. [<xref rid="B31-jcm-13-07729" ref-type="bibr">31</xref>] described a multicentre experience of 6 DTC arising from SO in six different patients, analyzing their genetic characteristics by next-generation sequencing. Five of them were intra-ovarian PTC, all &#x0003c;1 cm and without risk factors, and were treated with gynaecological surgery only. One patient presented with a 3 cm PDC with vascular invasion and was therefore treated with a prophylactic TT + RAI (3.7 Gbq) with a complete response. No patients had disease recrudescence and/or died during the FU (mean 104 months).</p><sec><title>Study Synthesis: RAI Applications and Outcome</title><p>A total of 155 cases of DTC in SO were collected in the eleven studies included in the present systematic review. TT + RAI was performed in 22 patients (14.19%): in particular, in seven cases, it was proposed to patients with risk factors (e.g., vascular invasion, extraovarian local spread, dimension), in two cases in patients with concomitant thyroid cancer and in seven cases in patients with metastatic disease. The clinical reason for TT + RAI therapy in the last six patients described in the study by Goffredo P et al. [<xref rid="B6-jcm-13-07729" ref-type="bibr">6</xref>], such as their specific outcome, were not reported. Considering the other 16 patients treated with RAI, only one patient died due to disease complication or evolution (6.25%), and it was a subject with metastatic PDC. The seven patients with risk factors and the two with thyroid cancer achieved no evidence of disease (NED) at the end of their follow-up, whereas the other six subjects with metastases had a partial response in five cases and a complete response in one case.</p></sec></sec><sec sec-type="discussion" id="sec4-jcm-13-07729"><title>4. Discussion</title><p>DTC in MSO represents a rare occurrence and a significant clinical challenge in its treatment, in particular, because of the absence of clear and well-established guidelines for its management. Most single-center or professional experience consists of a limited number of cases, particularly with regard to the role of the nuclear medicine physician and the possibility of RAI treatment. In our review, only a small proportion of patients with a diagnosis of DTC in SO received TT + RAI (14.19%), and, in particular, at least one of the 155 subjects described did not receive therapy despite peritoneal metastases: other literature reviews, as we could read later, reported greater use of RAI therapy in MSO disease. The outcome of patients treated with RAI could be considered good, with only one death in the only subject with poorly differentiated disease: the poor response to RAI treatment and prognosis of poorly differentiated thyroid cancer is unfortunate, well-known data [<xref rid="B33-jcm-13-07729" ref-type="bibr">33</xref>,<xref rid="B34-jcm-13-07729" ref-type="bibr">34</xref>]. Regarding the literature in favor of RAI treatment, a recent review by Cui Y et al. [<xref rid="B4-jcm-13-07729" ref-type="bibr">4</xref>] considered 144 cases of MSO described in the literature: they reported 32.14% of patients with DTC in SO treated with TT + RAI, a figure higher than in our review (14.19%) probably because they also included case reports and a possible reduction in mortality in patients treated with RAI (1.5% less than in patients who did not receive it), but without statistical significance. DeSimone CP et al. [<xref rid="B35-jcm-13-07729" ref-type="bibr">35</xref>] also described a possible larger use of RAI in the management of DTC arising in SO, reporting 24 cases with eight recurrences during follow-up, all in the group of patients who did not receive this therapy. Furthermore, Irena Batog W et al. [<xref rid="B36-jcm-13-07729" ref-type="bibr">36</xref>] proposed to consider RAI therapy in patients with suspected and/or diagnosed concomitant thyroid cancer. Instead, a review by Li S et al. [<xref rid="B37-jcm-13-07729" ref-type="bibr">37</xref>] considered 194 cases of MSO reported in the literature, 65 (35.6%) of which were treated with TT + RAI, and reported no significant correlation between RAI therapy and OS. However, the author&#x02019;s consideration of the poor prognosis of patients with PDC described in the study is noteworthy, with the hypothesis of a correlation with the known poor response to RAI therapy in this type of disease. Another consideration to underline is the possible use of RAI in patients with advanced-stage diseases that are intrinsically characterized by poor prognosis: in this setting, the lack of statistical difference between patients treated with this therapy and those not treated could be read as in favor of RAI therapy. On the same side, considering only patients with metastases, Robboy et al. [<xref rid="B38-jcm-13-07729" ref-type="bibr">38</xref>] described 27 cases of women with metastatic MSO, partly reported in the literature partly seen by the authors. In particular, twelve subjects (44.44%) received I131 with the worst outcome: five patients (41.67%) had a disease-related death, but one received RAI terminally (one month before death) and after chemotherapy, and three had an OS &#x0003e; 25 years anyway. The remaining group of 15 patients who did not receive RAI was characterized by five disease-related deaths (33.33%), but it is noteworthy that the FIGO stage was I or II in 75% of this group of patients, with some metastases treatable with major abdomino-pelvic surgery, instead only 50% in patients who received RAI. Lastly, Egan C et al. [<xref rid="B39-jcm-13-07729" ref-type="bibr">39</xref>] proposed a risk stratification model by adapting the 2015 American Thyroid Association risk guidelines for MSO patients, considering parameters such as the presence of metastases, extraovarian extension, lymphovascular invasion, lymph node status, surgical margins, tumor size, and grade, similarly as proposed by Addley S et al. [<xref rid="B26-jcm-13-07729" ref-type="bibr">26</xref>]: they found that the stratification obtained showed a good correlation between high-risk class and OS, but a poor correspondence with use of RAI therapy, as usually performed in classical thyroid cancer. In fact, only 30% of patients classified as high-risk in the National Cancer Database (NCDB) and 41% of patients in the Surveillance, Epidemiology, and End Results Registry (SEER) were treated with RAI. The authors highlighted this discrepancy in their conclusion and suggested further studies to determine how patients could benefit from this therapy. In general, RAI was suggested in fewer patients (19 to 158, 12.03% of patients from NCDB and 18 to 95, 18.95% of patients from SEER). Despite some studies describing the possible correlation between BRAF mutation status and the presence of DTC in SO [<xref rid="B4-jcm-13-07729" ref-type="bibr">4</xref>,<xref rid="B40-jcm-13-07729" ref-type="bibr">40</xref>,<xref rid="B41-jcm-13-07729" ref-type="bibr">41</xref>], no papers described and/or analyzed the possible relationship between BRAF mutations and patient prognosis and/or the possibility of performing TT + RAI. To summarize and look at the literature, TT + RAI was not routinely proposed, and the percentage of patients treated with RAI ranged from 12.03% to 35.6%. There is a general consensus, as occurred in classical thyroid cancer, to perform TT + RAI in patients with distant metastases, mandatory in patients without the possibility of radical major abdomino-pelvic surgery, also considering the absence of data on the possible use of target therapy in literature, actually limited by few cases reports [<xref rid="B42-jcm-13-07729" ref-type="bibr">42</xref>,<xref rid="B43-jcm-13-07729" ref-type="bibr">43</xref>]. The only exception could be represented by young patients with only intra-abdominal disease and looking for pregnancy, as described by Ryu HJ et al. [<xref rid="B23-jcm-13-07729" ref-type="bibr">23</xref>]. The same therapeutic program was generally recommended for patients with concomitant suspected or confirmed thyroid cancer [<xref rid="B4-jcm-13-07729" ref-type="bibr">4</xref>,<xref rid="B36-jcm-13-07729" ref-type="bibr">36</xref>]. The possibility of proposing RAI in patients with potential risk factors for disease recurrence is still debated and not clearly established: the first problem is represented by the absence of clear, endorsed classifications of patients considering these risk factors; the second problem, stemming from the rarity of the disease, is the absence of a prospective study confronting patients treated with RAI and patients not treated. Considering the actual common management of classical thyroid cancer, it is presumable that at least a part of patients with risk factors could benefit from this therapeutic approach, as suggested by Addley S et al. [<xref rid="B26-jcm-13-07729" ref-type="bibr">26</xref>], Smith LP et al. [<xref rid="B44-jcm-13-07729" ref-type="bibr">44</xref>] and explored in the study by Egan C et al. [<xref rid="B39-jcm-13-07729" ref-type="bibr">39</xref>]. In these patients, discussion in the multidisciplinary team (MDT) is probably indeed preferred, presenting both solutions (TT + RAI vs. conservative approach) and explaining the limited data on disease management. At the same time, a consensus between experts and the scientific community should be explored to establish a common line of treatment for this rare disease. Summing up, as we mentioned before, the possible use of RAI in DTC derived from SO is still debated since several issues are present when considering it, such as the absence of clinical guidelines and general professional experience in its management. In addition, different data reported in the literature suggest that this therapy could be considered in a considerable number of patients, particularly for patients with aggressive diseases such as the presence of metastases, in the case of relapsed neoplasms, or in the presence of aggressive pathological features. The limited prognostic data presented in this review seems to support these proposals. Our personal experience, even though limited, endorses these findings since only patients with risk factors have been treated with RAI and had a good prognosis during the follow-up. Lastly, it is useful to remark that an MDT approach is mandatory to achieve patient-centered treatment planning. Some limitations, due to the characteristics of the studies included, affect our systematic review. First, some of the studies are characterized by limited cohorts, a limitation intrinsically related to the rarity of the disease. In addition, some data essential for the identification of patients who could be treated with RAI appeared lacking in a few studies. Moreover, the different specializations of the physician responsible for the therapeutic management and planning of these patients could result in different therapeutic approaches. Lastly, all of the studies included in the review had a retrospective design. Based on these facts, no meta-analysis of the data retrieved could be performed.</p></sec><sec sec-type="conclusions" id="sec5-jcm-13-07729"><title>5. Conclusions</title><p>The results of the systematic review suggest that RAI following TT in DTC derived from SO is typically considered for metastatic patients and in cases of disease relapse. Patients with low-aggressive histologies and intraovarian diseases required only a surgical approach. In the other cases, such as extraovarian extension of the disease, vascular invasion, and/or the presence of aggressive histology, RAI treatment appeared possible and should be discussed with the patient in an MDT setting.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-jcm-13-07729"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/jcm13247729/s1">https://www.mdpi.com/article/10.3390/jcm13247729/s1</uri>, PRISMA Checklist.</p><supplementary-material id="jcm-13-07729-s001" position="float" content-type="local-data"><media xlink:href="jcm-13-07729-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, P.B.; methodology, P.B. and F.D.; writing&#x02014;original draft preparation, P.B.; writing&#x02014;review and editing, P.B., F.D., V.Z., E.G., M.C., C.C., G.L.V. and F.B. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data supporting the reported results can be found using the public PubMed/MEDLINE, Scopus, and Web of Science databases.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-jcm-13-07729"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gottschalk</surname><given-names>S.</given-names></name>
</person-group><article-title>Ein neuer typus einer kleincystischen bosartigen eierstockgeschwulst</article-title><source>Arch. Gynak.</source><year>1899</year><volume>59</volume><fpage>676</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1007/BF01948483</pub-id></element-citation></ref><ref id="B2-jcm-13-07729"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kondi-Pafiti</surname><given-names>A.</given-names></name>
<name><surname>Mavrigiannaki</surname><given-names>P.</given-names></name>
<name><surname>Grigoriadis</surname><given-names>C.</given-names></name>
<name><surname>Kontogianni-Katsarou</surname><given-names>K.</given-names></name>
<name><surname>Mellou</surname><given-names>A.</given-names></name>
<name><surname>Kleanthis</surname><given-names>C.K.</given-names></name>
<name><surname>Liapis</surname><given-names>A.</given-names></name>
</person-group><article-title>Monodermal teratomas (struma ovarii). Clinicopathological characteristics of 11 cases and literature review</article-title><source>Eur. J. Gynaecol. Oncol.</source><year>2011</year><volume>32</volume><fpage>657</fpage><lpage>659</lpage><pub-id pub-id-type="pmid">22335029</pub-id>
</element-citation></ref><ref id="B3-jcm-13-07729"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wei</surname><given-names>S.</given-names></name>
<name><surname>Baloch</surname><given-names>Z.W.</given-names></name>
<name><surname>LiVolsi</surname><given-names>V.A.</given-names></name>
</person-group><article-title>Pathology of Struma Ovarii: A Report of 96 Cases</article-title><source>Endocr. Pathol.</source><year>2015</year><volume>26</volume><fpage>342</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1007/s12022-015-9396-1</pub-id><pub-id pub-id-type="pmid">26374222</pub-id>
</element-citation></ref><ref id="B4-jcm-13-07729"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cui</surname><given-names>Y.</given-names></name>
<name><surname>Yao</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Zhao</surname><given-names>J.</given-names></name>
<name><surname>Dong</surname><given-names>J.</given-names></name>
<name><surname>Liao</surname><given-names>L.</given-names></name>
</person-group><article-title>The Clinical and Pathological Characteristics of Malignant Struma Ovarii: An Analysis of 144 Published Patients</article-title><source>Front. Oncol.</source><year>2021</year><volume>11</volume><elocation-id>645156</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2021.645156</pub-id><pub-id pub-id-type="pmid">33763376</pub-id>
</element-citation></ref><ref id="B5-jcm-13-07729"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Yang</surname><given-names>T.</given-names></name>
<name><surname>Xiang</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Deng</surname><given-names>S.</given-names></name>
</person-group><article-title>Clinical characteristics and survival outcomes of malignant struma ovarii confined to the ovary</article-title><source>BMC Cancer</source><year>2021</year><volume>21</volume><elocation-id>383</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-021-08118-7</pub-id><pub-id pub-id-type="pmid">33836675</pub-id>
</element-citation></ref><ref id="B6-jcm-13-07729"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goffredo</surname><given-names>P.</given-names></name>
<name><surname>Sawka</surname><given-names>A.M.</given-names></name>
<name><surname>Pura</surname><given-names>J.</given-names></name>
<name><surname>Adam</surname><given-names>M.A.</given-names></name>
<name><surname>Roman</surname><given-names>S.A.</given-names></name>
<name><surname>Sosa</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Malignant struma ovarii: A population-level analysis of a large series of 68 patients</article-title><source>Thyroid</source><year>2015</year><volume>25</volume><fpage>211</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1089/thy.2014.0328</pub-id><pub-id pub-id-type="pmid">25375817</pub-id>
</element-citation></ref><ref id="B7-jcm-13-07729"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garg</surname><given-names>K.</given-names></name>
<name><surname>Soslow</surname><given-names>R.A.</given-names></name>
<name><surname>Rivera</surname><given-names>M.</given-names></name>
<name><surname>Tuttle</surname><given-names>M.R.</given-names></name>
<name><surname>Ghossein</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Histologically bland &#x0201c;extremely well differentiated&#x0201d; thyroid carcinomas arising in struma ovarii can recur and metastasize</article-title><source>Int. J. Gynecol. Pathol.</source><year>2009</year><volume>28</volume><fpage>222</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1097/PGP.0b013e31818a2b99</pub-id><pub-id pub-id-type="pmid">19620939</pub-id>
</element-citation></ref><ref id="B8-jcm-13-07729"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Robboy</surname><given-names>S.J.</given-names></name>
<name><surname>Shaco-Levy</surname><given-names>R.</given-names></name>
<name><surname>Peng</surname><given-names>R.Y.</given-names></name>
<name><surname>Snyder</surname><given-names>M.J.</given-names></name>
<name><surname>Donahue</surname><given-names>J.</given-names></name>
<name><surname>Bentley</surname><given-names>R.C.</given-names></name>
<name><surname>Bean</surname><given-names>S.</given-names></name>
<name><surname>Krigman</surname><given-names>H.R.</given-names></name>
<name><surname>Roth</surname><given-names>L.M.</given-names></name>
<name><surname>Young</surname><given-names>R.H.</given-names></name>
</person-group><article-title>Malignant struma ovarii: An analysis of 88 cases, including 27 with extraovarian spread</article-title><source>Int. J. Gynecol. Pathol.</source><year>2009</year><volume>28</volume><fpage>405</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1097/PGP.0b013e3181a27777</pub-id><pub-id pub-id-type="pmid">19696610</pub-id>
</element-citation></ref><ref id="B9-jcm-13-07729"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haugen</surname><given-names>B.R.</given-names></name>
<name><surname>Alexander</surname><given-names>E.K.</given-names></name>
<name><surname>Bible</surname><given-names>K.C.</given-names></name>
<name><surname>Doherty</surname><given-names>G.M.</given-names></name>
<name><surname>Mandel</surname><given-names>S.J.</given-names></name>
<name><surname>Nikiforov</surname><given-names>Y.E.</given-names></name>
<name><surname>Pacini</surname><given-names>F.</given-names></name>
<name><surname>Randolph</surname><given-names>G.W.</given-names></name>
<name><surname>Sawka</surname><given-names>A.M.</given-names></name>
<name><surname>Schlumberger</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer</article-title><source>Thyroid</source><year>2016</year><volume>26</volume><fpage>1</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1089/thy.2015.0020</pub-id><pub-id pub-id-type="pmid">26462967</pub-id>
</element-citation></ref><ref id="B10-jcm-13-07729"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Petranovi&#x00107; Ov&#x0010d;ari&#x0010d;ek</surname><given-names>P.</given-names></name>
<name><surname>Kreissl</surname><given-names>M.C.</given-names></name>
<name><surname>Campenni</surname><given-names>A.</given-names></name>
<name><surname>de Keizer</surname><given-names>B.</given-names></name>
<name><surname>Tuncel</surname><given-names>M.</given-names></name>
<name><surname>Vrachimis</surname><given-names>A.</given-names></name>
<name><surname>Deandreis</surname><given-names>D.</given-names></name>
<name><surname>Giovanella</surname><given-names>L.</given-names></name>
</person-group><article-title>SNMMI/EANM practice guideline vs. ETA Consensus Statement: Differences and similarities in approaching differentiated thyroid cancer management&#x02014;The EANM perspective</article-title><source>Eur. J. Nucl. Med. Mol. Imaging</source><year>2022</year><volume>49</volume><fpage>3959</fpage><lpage>3963</lpage><pub-id pub-id-type="doi">10.1007/s00259-022-05935-1</pub-id><pub-id pub-id-type="pmid">35947178</pub-id>
</element-citation></ref><ref id="B11-jcm-13-07729"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.Q.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Lin</surname><given-names>Y.S.</given-names></name>
</person-group><article-title>Delayed initial radioiodine therapy related to incomplete response in low- to intermediate-risk differentiated thyroid cancer</article-title><source>Clin. Endocrinol.</source><year>2018</year><volume>88</volume><fpage>601</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1111/cen.13551</pub-id></element-citation></ref><ref id="B12-jcm-13-07729"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Steinschneider</surname><given-names>M.</given-names></name>
<name><surname>Pitaro</surname><given-names>J.</given-names></name>
<name><surname>Koren</surname><given-names>S.</given-names></name>
<name><surname>Mizrakli</surname><given-names>Y.</given-names></name>
<name><surname>Benbassat</surname><given-names>C.</given-names></name>
<name><surname>Muallem Kalmovich</surname><given-names>L.</given-names></name>
</person-group><article-title>Differentiated Thyroid Cancer with Biochemical Incomplete Response: Clinico-Pathological Characteristics and Long Term Disease Outcomes</article-title><source>Cancers</source><year>2023</year><volume>13</volume><elocation-id>5422</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13215422</pub-id></element-citation></ref><ref id="B13-jcm-13-07729"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bellini</surname><given-names>P.</given-names></name>
<name><surname>Dondi</surname><given-names>F.</given-names></name>
<name><surname>Gatta</surname><given-names>E.</given-names></name>
<name><surname>Zilioli</surname><given-names>V.</given-names></name>
<name><surname>Albano</surname><given-names>D.</given-names></name>
<name><surname>Cappelli</surname><given-names>C.</given-names></name>
<name><surname>Bertagna</surname><given-names>F.</given-names></name>
</person-group><article-title>Prognostic role and characteristics of the indeterminate response in differentiated thyroid cancer: A systematic review</article-title><source>Endocrine</source><year>2024</year><volume>84</volume><fpage>812</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1007/s12020-024-03688-5</pub-id><pub-id pub-id-type="pmid">38265607</pub-id>
</element-citation></ref><ref id="B14-jcm-13-07729"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gambale</surname><given-names>C.</given-names></name>
<name><surname>Prete</surname><given-names>A.</given-names></name>
<name><surname>Contartese</surname><given-names>L.</given-names></name>
<name><surname>Torregrossa</surname><given-names>L.</given-names></name>
<name><surname>Bianchi</surname><given-names>F.</given-names></name>
<name><surname>Molinaro</surname><given-names>E.</given-names></name>
<name><surname>Materazzi</surname><given-names>G.</given-names></name>
<name><surname>Elisei</surname><given-names>R.</given-names></name>
<name><surname>Matrone</surname><given-names>A.</given-names></name>
</person-group><article-title>Usefulness of second <sup>131</sup>I treatment in biochemical persistent differentiated thyroid cancer patients</article-title><source>Eur. Thyroid. J.</source><year>2023</year><volume>12</volume><fpage>e230052</fpage><pub-id pub-id-type="doi">10.1530/ETJ-23-0052</pub-id><pub-id pub-id-type="pmid">37855417</pub-id>
</element-citation></ref><ref id="B15-jcm-13-07729"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Feng</surname><given-names>F.</given-names></name>
<name><surname>Wu</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Fu</surname><given-names>H.</given-names></name>
</person-group><article-title>The value of [<sup>18</sup>F]FDG PET/CT in avoiding overtreatment of <sup>131</sup>l avidity pulmonary metastasis of differentiated thyroid cancer</article-title><source>Endokrynol. Pol.</source><year>2023</year><volume>74</volume><fpage>385</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.5603/EP.a2023.0048</pub-id><pub-id pub-id-type="pmid">37577994</pub-id>
</element-citation></ref><ref id="B16-jcm-13-07729"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Albano</surname><given-names>D.</given-names></name>
<name><surname>Dondi</surname><given-names>F.</given-names></name>
<name><surname>Mazzoletti</surname><given-names>A.</given-names></name>
<name><surname>Bellini</surname><given-names>P.</given-names></name>
<name><surname>Rodella</surname><given-names>C.</given-names></name>
<name><surname>Bertagna</surname><given-names>F.</given-names></name>
</person-group><article-title>Prognostic Role of 2-[<sup>18</sup>F]FDG PET/CT Metabolic Volume Parameters in Patients Affected by Differentiated Thyroid Carcinoma with High Thyroglobulin Level, Negative <sup>131</sup>I WBS and Positive 2-[<sup>18</sup>F]-FDG PET/CT</article-title><source>Diagnostics</source><year>2021</year><volume>11</volume><elocation-id>2189</elocation-id><pub-id pub-id-type="doi">10.3390/diagnostics11122189</pub-id><pub-id pub-id-type="pmid">34943426</pub-id>
</element-citation></ref><ref id="B17-jcm-13-07729"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schlumberger</surname><given-names>M.</given-names></name>
<name><surname>Tahara</surname><given-names>M.</given-names></name>
<name><surname>Wirth</surname><given-names>L.J.</given-names></name>
<name><surname>Robinson</surname><given-names>B.</given-names></name>
<name><surname>Brose</surname><given-names>M.S.</given-names></name>
<name><surname>Elisei</surname><given-names>R.</given-names></name>
<name><surname>Habra</surname><given-names>M.A.</given-names></name>
<name><surname>Newbold</surname><given-names>K.</given-names></name>
<name><surname>Shah</surname><given-names>M.H.</given-names></name>
<name><surname>Hoff</surname><given-names>A.O.</given-names></name>
<etal/>
</person-group><article-title>Lenvatinib versus placebo in radioiodine-refractory thyroid cancer</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>372</volume><fpage>621</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1406470</pub-id><pub-id pub-id-type="pmid">25671254</pub-id>
</element-citation></ref><ref id="B18-jcm-13-07729"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Verburg</surname><given-names>F.A.</given-names></name>
<name><surname>H&#x000e4;nscheid</surname><given-names>H.</given-names></name>
<name><surname>Luster</surname><given-names>M.</given-names></name>
</person-group><article-title>Radioactive iodine (RAI) therapy for metastatic differentiated thyroid cancer</article-title><source>Best Pract. Res. Clin. Endocrinol. Metab.</source><year>2017</year><volume>31</volume><fpage>279</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1016/j.beem.2017.04.010</pub-id><pub-id pub-id-type="pmid">28911724</pub-id>
</element-citation></ref><ref id="B19-jcm-13-07729"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Albano</surname><given-names>D.</given-names></name>
<name><surname>Piccardo</surname><given-names>A.</given-names></name>
<name><surname>Rizzo</surname><given-names>A.</given-names></name>
<name><surname>Cuzzocrea</surname><given-names>M.</given-names></name>
<name><surname>Bottoni</surname><given-names>G.</given-names></name>
<name><surname>Bellini</surname><given-names>P.</given-names></name>
<name><surname>Bertagna</surname><given-names>F.</given-names></name>
<name><surname>Treglia</surname><given-names>G.</given-names></name>
</person-group><article-title>Diagnostic performance of 2-[<sup>18</sup>F]FDG PET/CT in recurrent differentiated thyroid cancer and elevated antithyroglobulin antibodies: An updated systematic review and bivariate meta-analysis</article-title><source>Endocrine</source><year>2024</year><pub-id pub-id-type="doi">10.1007/s12020-024-03989-9</pub-id><pub-id pub-id-type="pmid">39249633</pub-id>
</element-citation></ref><ref id="B20-jcm-13-07729"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zajkowska</surname><given-names>K.</given-names></name>
<name><surname>Cegla</surname><given-names>P.</given-names></name>
<name><surname>Dedecjus</surname><given-names>M.</given-names></name>
</person-group><article-title>Role of [<sup>18</sup>F]FDG PET/CT in the management of follicular cell-derived thyroid carcinoma</article-title><source>Cancer Imaging</source><year>2024</year><volume>24</volume><fpage>147</fpage><pub-id pub-id-type="doi">10.1186/s40644-024-00791-8</pub-id><pub-id pub-id-type="pmid">39468677</pub-id>
</element-citation></ref><ref id="B21-jcm-13-07729"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Page</surname><given-names>M.J.</given-names></name>
<name><surname>McKenzie</surname><given-names>J.E.</given-names></name>
<name><surname>Bossuyt</surname><given-names>P.M.</given-names></name>
<name><surname>Boutron</surname><given-names>I.</given-names></name>
<name><surname>Hoffmann</surname><given-names>T.C.</given-names></name>
<name><surname>Mulrow</surname><given-names>C.D.</given-names></name>
<name><surname>Shamseer</surname><given-names>L.</given-names></name>
<name><surname>Tetzlaff</surname><given-names>J.M.</given-names></name>
<name><surname>Akl</surname><given-names>E.A.</given-names></name>
<name><surname>Brennan</surname><given-names>S.E.</given-names></name>
<etal/>
</person-group><article-title>The PRISMA 2020 statement: An updated guideline for reporting systematic reviews</article-title><source>BMJ</source><year>2021</year><volume>372</volume><fpage>n71</fpage><!--<pub-id pub-id-type="pmcid">PMC8005924</pub-id>--><pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmid">33782057</pub-id>
</element-citation></ref><ref id="B22-jcm-13-07729"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Whiting</surname><given-names>P.F.</given-names></name>
<name><surname>Rutjes</surname><given-names>A.W.</given-names></name>
<name><surname>Westwood</surname><given-names>M.E.</given-names></name>
<name><surname>Mallett</surname><given-names>S.</given-names></name>
<name><surname>Deeks</surname><given-names>J.J.</given-names></name>
<name><surname>Reitsma</surname><given-names>J.B.</given-names></name>
<name><surname>Leeflang</surname><given-names>M.M.</given-names></name>
<name><surname>Sterne</surname><given-names>J.A.</given-names></name>
<name><surname>Bossuyt</surname><given-names>P.M.</given-names></name>
</person-group><article-title>QUADAS-2 Group. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies</article-title><source>Ann. Intern. Med.</source><year>2011</year><volume>155</volume><fpage>529</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-155-8-201110180-00009</pub-id><pub-id pub-id-type="pmid">22007046</pub-id>
</element-citation></ref><ref id="B23-jcm-13-07729"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ryu</surname><given-names>H.J.</given-names></name>
<name><surname>Leem</surname><given-names>D.E.</given-names></name>
<name><surname>Yoo</surname><given-names>J.H.</given-names></name>
<name><surname>Kim</surname><given-names>T.H.</given-names></name>
<name><surname>Kim</surname><given-names>S.W.</given-names></name>
<name><surname>Chung</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Clinical Manifestations of Malignant Struma Ovarii: A Retrospective Case Series in a Tertiary Hospital in Korea</article-title><source>Endocrinol. Metab.</source><year>2024</year><volume>39</volume><fpage>461</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.3803/EnM.2023.1863</pub-id><pub-id pub-id-type="pmid">38721636</pub-id>
</element-citation></ref><ref id="B24-jcm-13-07729"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gadducci</surname><given-names>A.</given-names></name>
<name><surname>Giuliani</surname><given-names>D.</given-names></name>
<name><surname>Cosio</surname><given-names>S.</given-names></name>
<name><surname>Lissoni</surname><given-names>A.</given-names></name>
<name><surname>Ferrero</surname><given-names>A.M.</given-names></name>
<name><surname>Landoni</surname><given-names>F.</given-names></name>
</person-group><article-title>Clinical Outcome of Patients with Malignant Tumors Associated With Mature Cystic Teratomas of the Ovary: A Retrospective Multicenter Italian Study</article-title><source>Anticancer Res.</source><year>2019</year><volume>39</volume><fpage>2513</fpage><lpage>2517</lpage><pub-id pub-id-type="doi">10.21873/anticanres.13372</pub-id><pub-id pub-id-type="pmid">31092447</pub-id>
</element-citation></ref><ref id="B25-jcm-13-07729"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Hong</surname><given-names>R.</given-names></name>
<name><surname>Yin</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>T.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
</person-group><article-title>Incidence, clinical characteristics, and survival outcomes of ovarian strumal diseases: A retrospective cohort study</article-title><source>BMC Womens Health</source><year>2023</year><volume>23</volume><elocation-id>497</elocation-id><pub-id pub-id-type="doi">10.1186/s12905-023-02624-5</pub-id><pub-id pub-id-type="pmid">37726744</pub-id>
</element-citation></ref><ref id="B26-jcm-13-07729"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Addley</surname><given-names>S.</given-names></name>
<name><surname>Mihai</surname><given-names>R.</given-names></name>
<name><surname>Alazzam</surname><given-names>M.</given-names></name>
<name><surname>Dhar</surname><given-names>S.</given-names></name>
<name><surname>Soleymani Majd</surname><given-names>H.</given-names></name>
</person-group><article-title>Malignant struma ovarii: Surgical, histopathological and survival outcomes for thyroid-type carcinoma of struma ovarii with recommendations for standardising multi-modal management. A retrospective case series sharing the experience of a single institution over 10 years</article-title><source>Arch. Gynecol. Obstet.</source><year>2021</year><volume>303</volume><fpage>863</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1007/s00404-021-05969-0</pub-id><pub-id pub-id-type="pmid">33512594</pub-id>
</element-citation></ref><ref id="B27-jcm-13-07729"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Devaney</surname><given-names>K.</given-names></name>
<name><surname>Snyder</surname><given-names>R.</given-names></name>
<name><surname>Norris</surname><given-names>H.J.</given-names></name>
<name><surname>Tavassoli</surname><given-names>F.A.</given-names></name>
</person-group><article-title>Proliferative and histologically malignant struma ovarii: A clinicopathologic study of 54 cases</article-title><source>Int. J. Gynecol. Pathol.</source><year>1993</year><volume>12</volume><fpage>333</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1097/00004347-199310000-00008</pub-id><pub-id pub-id-type="pmid">8253550</pub-id>
</element-citation></ref><ref id="B28-jcm-13-07729"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Yang</surname><given-names>T.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Shi</surname><given-names>H.</given-names></name>
<name><surname>Cheng</surname><given-names>N.</given-names></name>
<name><surname>Lang</surname><given-names>J.</given-names></name>
</person-group><article-title>FIGO Stage IV and Age Over 55 Years as Prognostic Predicators in Patients with Metastatic Malignant Struma Ovarii</article-title><source>Front. Oncol.</source><year>2020</year><volume>10</volume><elocation-id>584917</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2020.584917</pub-id><pub-id pub-id-type="pmid">33117719</pub-id>
</element-citation></ref><ref id="B29-jcm-13-07729"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roth</surname><given-names>L.M.</given-names></name>
<name><surname>Miller</surname><given-names>A.W.</given-names><suffix>3rd</suffix></name>
<name><surname>Talerman</surname><given-names>A.</given-names></name>
</person-group><article-title>Typical thyroid-type carcinoma arising in struma ovarii: A report of 4 cases and review of the literature</article-title><source>Int. J. Gynecol. Pathol.</source><year>2008</year><volume>27</volume><fpage>496</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1097/PGP.0b013e31816a74c6</pub-id><pub-id pub-id-type="pmid">18753973</pub-id>
</element-citation></ref><ref id="B30-jcm-13-07729"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marti</surname><given-names>J.L.</given-names></name>
<name><surname>Clark</surname><given-names>V.E.</given-names></name>
<name><surname>Harper</surname><given-names>H.</given-names></name>
<name><surname>Chhieng</surname><given-names>D.C.</given-names></name>
<name><surname>Sosa</surname><given-names>J.A.</given-names></name>
<name><surname>Roman</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Optimal surgical management of well-differentiated thyroid cancer arising in struma ovarii: A series of 4 patients and a review of 53 reported cases</article-title><source>Thyroid</source><year>2012</year><volume>22</volume><fpage>400</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1089/thy.2011.0162</pub-id><pub-id pub-id-type="pmid">22181336</pub-id>
</element-citation></ref><ref id="B31-jcm-13-07729"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Poli</surname><given-names>R.</given-names></name>
<name><surname>Scatolini</surname><given-names>M.</given-names></name>
<name><surname>Grosso</surname><given-names>E.</given-names></name>
<name><surname>Maletta</surname><given-names>F.</given-names></name>
<name><surname>Gallo</surname><given-names>M.</given-names></name>
<name><surname>Liscia</surname><given-names>D.</given-names></name>
<name><surname>Nelva</surname><given-names>A.</given-names></name>
<name><surname>Cesario</surname><given-names>F.</given-names></name>
<name><surname>Forte</surname><given-names>G.</given-names></name>
<name><surname>Metovic</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Malignant struma ovarii: Next-generation sequencing of six cases revealed Nras, Braf, and Jak3 mutations</article-title><source>Endocrine</source><year>2021</year><volume>71</volume><fpage>216</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1007/s12020-020-02438-7</pub-id><pub-id pub-id-type="pmid">32743766</pub-id>
</element-citation></ref><ref id="B32-jcm-13-07729"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yoo</surname><given-names>S.C.</given-names></name>
<name><surname>Chang</surname><given-names>K.H.</given-names></name>
<name><surname>Lyu</surname><given-names>M.O.</given-names></name>
<name><surname>Chang</surname><given-names>S.J.</given-names></name>
<name><surname>Ryu</surname><given-names>H.S.</given-names></name>
<name><surname>Kim</surname><given-names>H.S.</given-names></name>
</person-group><article-title>Clinical characteristics of struma ovarii</article-title><source>J. Gynecol. Oncol.</source><year>2008</year><volume>19</volume><fpage>135</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.3802/jgo.2008.19.2.135</pub-id><pub-id pub-id-type="pmid">19471561</pub-id>
</element-citation></ref><ref id="B33-jcm-13-07729"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Violetis</surname><given-names>O.</given-names></name>
<name><surname>Konstantakou</surname><given-names>P.</given-names></name>
<name><surname>Spyroglou</surname><given-names>A.</given-names></name>
<name><surname>Xydakis</surname><given-names>A.</given-names></name>
<name><surname>Kekis</surname><given-names>P.B.</given-names></name>
<name><surname>Tseleni</surname><given-names>S.</given-names></name>
<name><surname>Kolomodi</surname><given-names>D.</given-names></name>
<name><surname>Konstadoulakis</surname><given-names>M.</given-names></name>
<name><surname>Mastorakos</surname><given-names>G.</given-names></name>
<name><surname>Theochari</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>The Long Journey towards Personalized Targeted Therapy in Poorly Differentiated Thyroid Carcinoma (PDTC): A Case Report and Systematic Review</article-title><source>J. Pers. Med.</source><year>2024</year><volume>14</volume><elocation-id>654</elocation-id><pub-id pub-id-type="doi">10.3390/jpm14060654</pub-id><pub-id pub-id-type="pmid">38929875</pub-id>
</element-citation></ref><ref id="B34-jcm-13-07729"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Giovanella</surname><given-names>L.</given-names></name>
<name><surname>Tuncel</surname><given-names>M.</given-names></name>
<name><surname>Aghaeel</surname><given-names>A.</given-names></name>
<name><surname>Campenni</surname><given-names>A.</given-names></name>
<name><surname>De Virgilio</surname><given-names>A.</given-names></name>
<name><surname>Petranovi&#x00107; Ov&#x0010d;ari&#x0010d;ek</surname><given-names>P.</given-names></name>
</person-group><article-title>Theranostics of Thyroid Cancer</article-title><source>Semin. Nucl. Med.</source><year>2024</year><volume>54</volume><fpage>470</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1053/j.semnuclmed.2024.01.011</pub-id><pub-id pub-id-type="pmid">38503602</pub-id>
</element-citation></ref><ref id="B35-jcm-13-07729"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>DeSimone</surname><given-names>C.P.</given-names></name>
<name><surname>Lele</surname><given-names>S.M.</given-names></name>
<name><surname>Modesitt</surname><given-names>S.C.</given-names></name>
</person-group><article-title>Malignant struma ovarii: A case report and analysis of cases reported in the literature with focus on survival and I<sup>131</sup> therapy</article-title><source>Gynecol. Oncol.</source><year>2003</year><volume>89</volume><fpage>543</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1016/S0090-8258(03)00141-0</pub-id><pub-id pub-id-type="pmid">12798728</pub-id>
</element-citation></ref><ref id="B36-jcm-13-07729"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Batog</surname><given-names>I.W.</given-names></name>
<name><surname>Riain</surname><given-names>C.&#x000d3;.</given-names></name>
<name><surname>Abu Saadeh</surname><given-names>F.</given-names></name>
</person-group><article-title>The dilemma of managing thyroid gland after incidental diagnosis of malignant struma Ovarii. Is radical thyroidectomy and radioactive iodine Necessary? A case report and literature review</article-title><source>Gynecol. Oncol. Rep.</source><year>2023</year><volume>47</volume><fpage>101189</fpage><pub-id pub-id-type="doi">10.1016/j.gore.2023.101189</pub-id><pub-id pub-id-type="pmid">37128251</pub-id>
</element-citation></ref><ref id="B37-jcm-13-07729"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shaco-Levy</surname><given-names>R.</given-names></name>
<name><surname>Bean</surname><given-names>S.M.</given-names></name>
<name><surname>Bentley</surname><given-names>R.C.</given-names></name>
<name><surname>Robboy</surname><given-names>S.J.</given-names></name>
</person-group><article-title>Natural history of biologically malignant struma ovarii: Analysis of 27 cases with extraovarian spread</article-title><source>Int. J. Gynecol. Pathol.</source><year>2010</year><volume>29</volume><fpage>212</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1097/PGP.0b013e3181bfb133</pub-id><pub-id pub-id-type="pmid">20407319</pub-id>
</element-citation></ref><ref id="B38-jcm-13-07729"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Kong</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Yin</surname><given-names>M.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
</person-group><article-title>Survival Outcomes and Prognostic Predictors in Patients with Malignant Struma Ovarii</article-title><source>Front. Med.</source><year>2021</year><volume>8</volume><elocation-id>774691</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2021.774691</pub-id><pub-id pub-id-type="pmid">35004743</pub-id>
</element-citation></ref><ref id="B39-jcm-13-07729"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Egan</surname><given-names>C.</given-names></name>
<name><surname>Stefanova</surname><given-names>D.</given-names></name>
<name><surname>Thiesmeyer</surname><given-names>J.W.</given-names></name>
<name><surname>Lee</surname><given-names>Y.J.</given-names></name>
<name><surname>Greenberg</surname><given-names>J.</given-names></name>
<name><surname>Beninato</surname><given-names>T.</given-names></name>
<name><surname>Zarnegar</surname><given-names>R.</given-names></name>
<name><surname>Christos</surname><given-names>P.J.</given-names></name>
<name><surname>Klein</surname><given-names>I.L.</given-names></name>
<name><surname>Fahey</surname><given-names>T.J.</given-names><suffix>3rd</suffix></name>
<etal/>
</person-group><article-title>Proposed Risk Stratification and Patterns of Radioactive Iodine Therapy in Malignant Struma Ovarii</article-title><source>Thyroid</source><year>2022</year><volume>32</volume><fpage>1101</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1089/thy.2022.0145</pub-id><pub-id pub-id-type="pmid">35765923</pub-id>
</element-citation></ref><ref id="B40-jcm-13-07729"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Neyrand</surname><given-names>S.</given-names></name>
<name><surname>Trecourt</surname><given-names>A.</given-names></name>
<name><surname>Lopez</surname><given-names>J.</given-names></name>
<name><surname>Just</surname><given-names>P.A.</given-names></name>
<name><surname>Descotes</surname><given-names>F.</given-names></name>
<name><surname>Borson-Chazot</surname><given-names>F.</given-names></name>
<name><surname>Ray-Coquard</surname><given-names>I.</given-names></name>
<name><surname>Decaussin-Petrucci</surname><given-names>M.</given-names></name>
<name><surname>Devouassoux-Shisheboran</surname><given-names>M.</given-names></name>
</person-group><article-title>Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and TERT promoter alterations favour malignant struma ovarii</article-title><source>Histopathology</source><year>2024</year><volume>84</volume><fpage>291</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1111/his.15052</pub-id><pub-id pub-id-type="pmid">37771077</pub-id>
</element-citation></ref><ref id="B41-jcm-13-07729"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schmidt</surname><given-names>J.</given-names></name>
<name><surname>Derr</surname><given-names>V.</given-names></name>
<name><surname>Heinrich</surname><given-names>M.C.</given-names></name>
<name><surname>Crum</surname><given-names>C.P.</given-names></name>
<name><surname>Fletcher</surname><given-names>J.A.</given-names></name>
<name><surname>Corless</surname><given-names>C.L.</given-names></name>
<name><surname>Nos&#x000e9;</surname><given-names>V.</given-names></name>
</person-group><article-title>BRAF in papillary thyroid carcinoma of ovary (struma ovarii)</article-title><source>Am. J. Surg. Pathol.</source><year>2007</year><volume>31</volume><fpage>1337</fpage><lpage>1343</lpage><pub-id pub-id-type="doi">10.1097/PAS.0b013e31802f5404</pub-id><pub-id pub-id-type="pmid">17721188</pub-id>
</element-citation></ref><ref id="B42-jcm-13-07729"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Taha</surname><given-names>T.</given-names></name>
<name><surname>Abu-Sini</surname><given-names>H.</given-names></name>
<name><surname>Billan</surname><given-names>S.</given-names></name>
</person-group><article-title>Tyrosine kinase inhibitor treatment and long-term follow-up for metastatic malignant struma ovarii</article-title><source>Pediatr. Hematol. Oncol.</source><year>2022</year><volume>39</volume><fpage>769</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1080/08880018.2022.2064021</pub-id><pub-id pub-id-type="pmid">35502916</pub-id>
</element-citation></ref><ref id="B43-jcm-13-07729"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Seban</surname><given-names>R.D.</given-names></name>
<name><surname>Bozec</surname><given-names>L.</given-names></name>
<name><surname>Nascimento-Leite</surname><given-names>C.</given-names></name>
<name><surname>Champion</surname><given-names>L.</given-names></name>
</person-group><article-title>Metabolic Response by <sup>18</sup>F-FDG PET/CT in Metastatic Malignant Struma Ovarii Treated with Targeted Therapies</article-title><source>Clin. Nucl. Med.</source><year>2021</year><volume>46</volume><fpage>52</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1097/RLU.0000000000003374</pub-id><pub-id pub-id-type="pmid">33181745</pub-id>
</element-citation></ref><ref id="B44-jcm-13-07729"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>L.P.</given-names></name>
<name><surname>Brubaker</surname><given-names>L.W.</given-names></name>
<name><surname>Wolsky</surname><given-names>R.J.</given-names></name>
</person-group><article-title>It Does Exist! Diagnosis and Management of Thyroid Carcinomas Originating in Struma Ovarii</article-title><source>Surg. Pathol. Clin.</source><year>2023</year><volume>16</volume><fpage>75</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.path.2022.09.008</pub-id><pub-id pub-id-type="pmid">36739168</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="jcm-13-07729-f001"><label>Figure 1</label><caption><p>Flowchart of the research of eligible studies about patients with DTC in SO.</p></caption><graphic xlink:href="jcm-13-07729-g001" position="float"/></fig><fig position="float" id="jcm-13-07729-f002"><label>Figure 2</label><caption><p>QUADAS-2 quality assessment for risk of bias and applicability regarding the studies included in the systematic review.</p></caption><graphic xlink:href="jcm-13-07729-g002" position="float"/></fig><table-wrap position="float" id="jcm-13-07729-t001"><object-id pub-id-type="pii">jcm-13-07729-t001_Table 1</object-id><label>Table 1</label><caption><p>General characteristics of studies included in the review, first part.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">First Author</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref. No.</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Year</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Country</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">N. Pts. </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Age (Median) [Range]</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">DTC in SO:Other SO</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wei S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B3-jcm-13-07729" ref-type="bibr">3</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59 years [35, 72]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11:85</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Goffredo P</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B6-jcm-13-07729" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43 years [16, 79]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68:0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Garg K</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B7-jcm-13-07729" ref-type="bibr">7</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2009</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41.5 years [32, 64]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10:0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ryu HJ</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B23-jcm-13-07729" ref-type="bibr">23</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2024</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">South Korea</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48 years [30, 70]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15:155</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gadducci</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B24-jcm-13-07729" ref-type="bibr">24</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2019</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Italy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">na ^</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5:0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Li S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B25-jcm-13-07729" ref-type="bibr">25</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">China</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">na ^</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13:262</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Addley S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B26-jcm-13-07729" ref-type="bibr">26</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">na ^</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">na</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Devaney K</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-jcm-13-07729" ref-type="bibr">27</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1993</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50 years [30, 77]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13:41</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Roth LM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-jcm-13-07729" ref-type="bibr">29</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2008</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51 years [26, 70]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4:0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Marti JL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-jcm-13-07729" ref-type="bibr">30</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2012</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44 years [43, 57]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4:0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poli R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B31-jcm-13-07729" ref-type="bibr">31</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Italy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">64.5 years [52, 66]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6:0</td></tr></tbody></table><table-wrap-foot><fn><p>^ Data provided for all of the patients included in the study. USA: United States of America; na: not available; N.: number; Pts.: patients; DTC: differentiated thyroid cancer; SO: struma ovarii.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jcm-13-07729-t002"><object-id pub-id-type="pii">jcm-13-07729-t002_Table 2</object-id><label>Table 2</label><caption><p>General characteristics of studies included in the review, second part.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">First Author</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref. No.</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PTC:FTC of HDFC:Other</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">FU Time (Mean)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pelvic/Abdominal Surgery:TT:TT + RAI</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Intraovarian:Extraovarian at Diagnosis</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">M0:M1 at Diagnosis</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">NED After First Line Therapy</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wei S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B3-jcm-13-07729" ref-type="bibr">3</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10:1:0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">79 months [1, 204]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9:0:2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9:2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10:1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11:0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Goffredo P</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B6-jcm-13-07729" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">na</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96 months [2, 408]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">na:na:6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52:13 *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56:9 *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">na</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Garg K</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B7-jcm-13-07729" ref-type="bibr">7</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8:0:2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">54 months [12, 168]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10:0:0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10:0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10:0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ryu HJ</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B23-jcm-13-07729" ref-type="bibr">23</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7:4:4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33 months [4, 156] **</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10:4:1 ***</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12:3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12:3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11:2 **</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gadducci</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B24-jcm-13-07729" ref-type="bibr">24</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3:2:0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60 months [38, 203]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4:0:1 ***</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5:0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5:0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5:0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Li S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B25-jcm-13-07729" ref-type="bibr">25</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8:5:0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">74.4 months [9.6, 348]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12:0:1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10:3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10:3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11:2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Addley S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B26-jcm-13-07729" ref-type="bibr">26</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6:0:0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">na</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3:0:3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6:0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6:0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6:0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Devaney K</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-jcm-13-07729" ref-type="bibr">27</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11:2:0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87.6 months [24, 216]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13:0:0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12:1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13:0 ^^</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13:0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Roth LM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-jcm-13-07729" ref-type="bibr">29</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3:1:0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">na</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3:01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3:1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">na</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">na</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Marti JL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-jcm-13-07729" ref-type="bibr">30</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3:1:0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108 months [9.6, 156]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3:0:1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4:0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4:0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4:0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poli R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B31-jcm-13-07729" ref-type="bibr">31</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5:0:1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">104 months [24, 240]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5:0:1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6:0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6:0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6:0</td></tr></tbody></table><table-wrap-foot><fn><p>* Data on 65 patients; ** Data on 13 patients; *** 1 patient performed TT and RAI for DTC before the diagnosis of MSO; ^^ One patient presented peritoneal strumosis which was not considered metastatic disease. PTC: papillary thyroid cancer; FTC: follicular thyroid cancer; HDFC: highly differentiated follicular cancer; TT: total thyroidectomy; RAI: radioiodine; FU: follow up; M0: absence of distant metastases; M1: presence of distant metastases; NED: non evidence of disease; na: not available.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jcm-13-07729-t003"><object-id pub-id-type="pii">jcm-13-07729-t003_Table 3</object-id><label>Table 3</label><caption><p>General characteristics of studies included in the review, third part.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">First Author</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref. No.</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Disease Relapse:No Disease Relapse During FU</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">RAI After Relapse</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wei S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B3-jcm-13-07729" ref-type="bibr">3</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1:10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">na</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Goffredo P</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B6-jcm-13-07729" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">na</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">na</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Garg K</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B7-jcm-13-07729" ref-type="bibr">7</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2:8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ryu HJ</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B23-jcm-13-07729" ref-type="bibr">23</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0:11 ****</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">na</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gadducci</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B24-jcm-13-07729" ref-type="bibr">24</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0:5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">na</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Li S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B25-jcm-13-07729" ref-type="bibr">25</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3:8 *****</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Addley S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B26-jcm-13-07729" ref-type="bibr">26</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0:6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">na</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Devaney K</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-jcm-13-07729" ref-type="bibr">27</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0:13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">na</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Roth LM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-jcm-13-07729" ref-type="bibr">29</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">na</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">na</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Marti JL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-jcm-13-07729" ref-type="bibr">30</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0:4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">na</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poli R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B31-jcm-13-07729" ref-type="bibr">31</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0:6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">na</td></tr></tbody></table><table-wrap-foot><fn><p>**** Data on 11 patients, plus 2 patients were alive with disease; ***** Data on 11 patients NED after first-line treatment. l RAI: radioiodine; FU: follow up.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jcm-13-07729-t004"><object-id pub-id-type="pii">jcm-13-07729-t004_Table 4</object-id><label>Table 4</label><caption><p>Main results of studies included in the review.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">First Author</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref. No.</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Setting</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Main Findings</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TT + RAI</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wei S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B3-jcm-13-07729" ref-type="bibr">3</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Describe the pathology of SO in a single center experience. 11 of 96 of them were characterized as DTC in SO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PTC was the most frequent variant of DTC in SO (90.9%).<break/>TT and further RAI were performed only in 2 patients.<break/>The only 1 PTC patients with metastases discovered during follow up was also the only 1 with extraovarian spread at diagnosis.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RAI was performed in 2 patients: one presented a PTC fullicular variant (FVPTC) with round<break/>ligament involvement at diagnosis, the other one a FVPTC of 2.5 cm at diagnosis</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Goffredo P</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B6-jcm-13-07729" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Describe the pathology, treatment and prognosis of MSO in the large database of Surveillance, Epidemiology, and End Results (SEER).<break/>68 Patient with MSO defined as histologically identical to DTC were selected.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Radiation was not commonly administered as part of the<break/>treatment algorithm: only 6 patient received RAI (5 alone, 1 with EBRT).<break/>Overall survival rates (OSR) at 5, 10, and 20 years were 96.7%, 94.3%, and 84.9%<break/>respectively.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RAI was performed in 6 patients, particularly in 3 patients with concomitant or subsequent thyroid cancer. Histology was not reported.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Garg K</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B7-jcm-13-07729" ref-type="bibr">7</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Describe the histopathology of MSO in a single center experience. 10 Patients with DTC developed in SO were described.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TT and further RAI were performed in the only 2 patients with metastases and/or disease relapse. Three patients with risk factor were treated conservatively. No cases of concomitant thyroid cancer were detected.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RAI was performed in 2 patients with a FVPTC in SO who developed metastases. In one case whole body scan (WBS) after RAI reveal a large liver metastasis. Both were alive with disease at the end of follow up.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ryu HJ</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B23-jcm-13-07729" ref-type="bibr">23</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Describe the pathology of SO in a single center experience. 15 of 170 of them were characterized as DTC in SO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PTC variant was the most frequent variant of DTC in SO (46.7%). Four patients presented also thyroid cancer.<break/>TT was performed in 4 patients, 3 for the thyroid cancer and one for MSO with metastases. Further RAI was performed in 3 of these patients.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RAI was performed in 2 patients with thyroid cancer and only in one case of MSO with metastases.<break/>No patients died for MSO.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gadducci</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B24-jcm-13-07729" ref-type="bibr">24</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Describe the pathology of malignant mature cystic teratoma in a multicentre experience. 5 of 23 of them were characterized as DTC.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PTC was the prevalent histotype (60%), all patients had a stage I FIGO. One patient had a previous thyroid cancer and performed RAI for them. No patients performed RAI after diagnosis of DTC in SO.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No patients presented metastases and/or died for MSO. No RAI was performed</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Li S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B25-jcm-13-07729" ref-type="bibr">25</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Analyzing the prevalence and pathology of ovarian strumal disease in a single center experience. 275 patients with ovarian stumal disease, particularly 13 with MSO, were selected.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PTC was the predominant histotype (46.2%), 3 patients had metastases at diagnosis. Six patients received adjuvant therapy, but only 1 patient received TT + RAI at diagnosis. Three patients had disease relapse and one of them who not performed RAI died.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RAI was performed in 1 patient with metastatic MSO at diagnosis and 2 with disease relapse: two of them had a partial response and one a complete response.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Addley S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B26-jcm-13-07729" ref-type="bibr">26</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Describe the pathology of MSO in a single center experience. 11 patients were analyzed, particularly 6 patients with DTC in SO.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patient with high risk, defined by aggressive<break/>histopathological features of PTC, a significant<break/>(&#x0003e;15 mm) disease deposit, close surgical margins and/or lympho-vascular invasion could benefit by TT and further RAI.<break/>None of the patients had metastases at diagnosis and none relapsed and/or died during FU.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TT + RAI was performed in 3 patients classified as &#x0201c;high risk&#x0201d;.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Devaney K</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-jcm-13-07729" ref-type="bibr">27</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Describe the pathology of MSO in a single center experience. 41 patients were analyzed, particularly 11 patients with DTC in SO.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PTC was the prevalent histotype (84.6%). All of the patients performed only surgical therapy. One patient presented peritoneal involvement, but no adjuvant therapy was performed.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No RAI was performed.<break/>No patients died for MSO.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Roth LM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-jcm-13-07729" ref-type="bibr">29</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Describe 4 cases of DTC in MSO occurred in two centers experience.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Three PTC and one poorly differentiated FTC in SO were reported. This last patient presented metastases at diagnosis and performed chemotherapy and RAI but died anyway after 3 years.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TT + RAI was performed in one patient with poorly differentiated FTC.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Marti JL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-jcm-13-07729" ref-type="bibr">30</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Describe 4 cases of DTC in MSO occurred in a single center experiences.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Three PTC and one FTC in SO were reported. One patient performed TT + RAI with the discovery of a pT3N1a thyroid cancer. All patient achieved NED after therapy, and none died.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TT + RAI was performed in one patient with complete response.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poli R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B31-jcm-13-07729" ref-type="bibr">31</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Analyzed the genetic characteristics of 6 DTC arised in SO in a multicentric experience</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PTC was the main histotype (80%). BRAF, JAK3 and NRAS mutations were found. All of the patients achieved NED after therapy and no disease recrudescence and/or death occurred during FU.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TT + RAI was performed in one patient with PDC in SO with vascular invasion with a complete response.</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: DTC: differentiated thyroid cancer; SO: struma ovarii; MSO: malignant struma ovarii; PTC: papillay thyroid cancer; FVPTC: PTC follicular variant; FTC: follicular thyroid cancer; PDC: poorly differentiated carcinoma; TT: total thyroidectomy; RAI: radioiodine; WBS: whole body scan; FU: follow up; EBRT: external beam radiation therapy; NED: non evidence of disease.</p></fn></table-wrap-foot></table-wrap></floats-group></article>